Zindoxifene
Jump to navigation
Jump to search
 | |
| Clinical data | |
|---|---|
| Synonyms | D-16726; NSC-341952 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H21NO4 |
| Molar mass | 351.402 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Zindoxifene (INN; former developmental code names D-16726, NSC-341952) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development in the 1980s and early 1990s for the treatment of breast cancer but was not marketed.[1] It showed estrogenic-like activity in preclinical studies and failed to demonstrate effectiveness as a treatment for breast cancer in clinical trials.[2][3] Zindoxifene was the lead compound of the distinct 2-phenylindole class of SERMs,[4][5] and the marketed SERM bazedoxifene was derived from the major active metabolite of zindoxifene, D-15414.[2][3] Zindoxifene was first described in 1984.[1]
References[edit]
- ^ a b J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1300–. ISBN 978-1-4757-2085-3.
- ^ a b Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan (23 July 2013). Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. pp. 170–. ISBN 978-3-0348-0664-0.
- ^ a b Hormones and Breast Cancer. Elsevier. 25 June 2013. pp. 32–. ISBN 978-0-12-416676-9.
- ^ Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. pp. 68–69. ISBN 978-3-642-58616-3.
- ^ International position paper on women's health and menopause : a comprehensive approach. DIANE Publishing. pp. 111–. ISBN 978-1-4289-0521-4.
External links[edit]
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
